Literature DB >> 9288544

Hyper- and hypoinsulinemia in type-2 diabetes: what may be wrong in the secretory mechanism of the B-cell.

H P Ammon1.   

Abstract

Type-2 diabetes frequently is the consequence of overnutrition causing overweight, which then produces insulin resistance. The following hyperglycemia induces permanent overstimulation of the insulin secretory machinery of the B-cell, which results in hyperinsulinemia and/or hypoinsulinemia. The mechanisms, however, of these disturbances are not understood so far. Animal models, which can be used to solve these questions, are, among others, long-term incubation of pancreatic islets in culture in the presence of high glucose and/or long-term infusion of rats with glucose. Using these models sensitization [Bedoya and Jeanrenaud, 1991; Leahy et al., 1987; Purrello et al., 1992; Thams, 1991; Thibault et al., 1993; Timmers et al., 1990] and/or desensitization of insulin release [Bedoya and Jeanrenaud, 1991; Leahy et al., 1987; Davalli et al., 1992; Eizirik et al., 1992; Bolaffi et al., 1988; Timmers et al., 1990] have been reported. Whether or not there is sensitization or desensitization depends on the glucose concentration [Eizirik et al., 1992; Leahy et al., 1986; Sako and Grill, 1990] and the duration of glucose action [Bedoya and Jeanrenaud, 1991; Bolaffi et al., 1988]. Both, sensitization and desensitization, appear to be reversible on return to normal glucose or mild hypoglycemia [Leahy and Weir, 1991; Svenson and Hellerström, 1991]. It seems, however, that there is a fluent change from the first occurring hyperinsulinemia to hypoinsulinemia. In this lecture I first want to talk about the possible mechanism of sensitization of insulin secretion discussing previous results we have obtained from rat islets isolated after a 48 hours period of i.v. infusion with 50% glucose. In the second part I will discuss some of the findings coming from the respective literature concerning desensitization of insulin secretion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9288544     DOI: 10.1055/s-0029-1211796

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  3 in total

1.  Induced desensitization of the insulinotropic effects of antidiabetic drugs, BTS 67 582 and tolbutamide.

Authors:  N H McClenaghan; A J Ball; P R Flatt
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  The Role of Obesity, Type 2 Diabetes, and Metabolic Factors in Pancreatic Cancer: A Mendelian Randomization Study.

Authors:  Robert Carreras-Torres; Mattias Johansson; Valerie Gaborieau; Philip C Haycock; Kaitlin H Wade; Caroline L Relton; Richard M Martin; George Davey Smith; Paul Brennan
Journal:  J Natl Cancer Inst       Date:  2017-09-01       Impact factor: 13.506

3.  Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium.

Authors:  Joanne W Elena; Emily Steplowski; Kai Yu; Patricia Hartge; Geoffrey S Tobias; Michelle J Brotzman; Stephen J Chanock; Rachael Z Stolzenberg-Solomon; Alan A Arslan; H Bas Bueno-de-Mesquita; Kathy Helzlsouer; Eric J Jacobs; Andrea LaCroix; Gloria Petersen; Wei Zheng; Demetrius Albanes; Naomi E Allen; Laufey Amundadottir; Ying Bao; Heiner Boeing; Marie-Christine Boutron-Ruault; Julie E Buring; J Michael Gaziano; Edward L Giovannucci; Eric J Duell; Göran Hallmans; Barbara V Howard; David J Hunter; Amy Hutchinson; Kevin B Jacobs; Charles Kooperberg; Peter Kraft; Julie B Mendelsohn; Dominique S Michaud; Domenico Palli; Lawrence S Phillips; Kim Overvad; Alpa V Patel; Leah Sansbury; Xiao-Ou Shu; Michael S Simon; Nadia Slimani; Dimitrios Trichopoulos; Kala Visvanathan; Jarmo Virtamo; Brian M Wolpin; Anne Zeleniuch-Jacquotte; Charles S Fuchs; Robert N Hoover; Myron Gross
Journal:  Cancer Causes Control       Date:  2012-10-31       Impact factor: 2.506

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.